NBW Capital’s Gilead Sciences GILD Stock Holding History

NBW Capital’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	$219K	Sell	1,971 -60	-3%	-$6.38K	0.05%	100
2025 Q1	$228K	Buy	+2,031	New	+$210K	0.05%	86
2024 Q4	–	Sell	-2,989	Closed	-$251K	–	94
2024 Q3	$251K	Buy	+2,989	New	+$228K	0.05%	90
2024 Q1	–	Sell	-3,020	Closed	-$245K	–	114
2023 Q4	$245K	Sell	3,020 -123	-4%	-$9.57K	0.05%	93
2023 Q3	$236K	Buy	3,143 +61	+2%	+$4.69K	0.06%	89
2023 Q2	$238K	Buy	3,082 +295	+11%	+$23.5K	0.06%	103
2023 Q1	$231K	Sell	2,787 -329	-11%	-$27.2K	0.06%	97
2022 Q4	$268K	Buy	+3,116	New	+$247K	0.07%	82

Other funds holding GILD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

NBW Capital's GILD Position: Q2 2025 in Review

NBW Capital reduced its Gilead Sciences (GILD) stake by 3% in Q2 2025, selling an estimated $6.38K and leaving 1,971 shares worth $219K. The position accounts for 0.05% of the portfolio, ranked #100.

NBW Capital first reported a position in GILD in Q4 2022 and has held it in 8 quarters since. The position peaked at $268K in Q4 2022. 2,024 funds tracked by Wall St. Rank hold GILD as of Q2 2025.

NBW Capital held 1,971 shares of Gilead Sciences worth $219K as of Q2 2025.
NBW Capital sold 60 Gilead Sciences shares in Q2 2025, an estimated $6.38K.
Gilead Sciences made up 0.05% of NBW Capital's portfolio in Q2 2025, its #100 holding.
NBW Capital first reported a position in Gilead Sciences in Q4 2022 and has held it in 8 quarters since.
NBW Capital's Gilead Sciences position peaked at $268K in Q4 2022.
2,024 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2025.

Based on NBW Capital's 13F filing for Q2 2025, filed 13 Aug 2025.